» Articles » PMID: 38644973

Knockdown of Partially Improves ALS Phenotype in a Transient Zebrafish Model

Overview
Specialty Cell Biology
Date 2024 Apr 22
PMID 38644973
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) corresponds to a neurodegenerative disorder marked by the progressive degeneration of both upper and lower motor neurons located in the brain, brainstem, and spinal cord. ALS can be broadly categorized into two main types: sporadic ALS (sALS), which constitutes approximately 90% of all cases, and familial ALS (fALS), which represents the remaining 10% of cases. Transforming growth factor type-β (TGF-β) is a cytokine involved in various cellular processes and pathological contexts, including inflammation and fibrosis. Elevated levels of TGF-β have been observed in the plasma and cerebrospinal fluid (CSF) of both ALS patients and mouse models. In this perspective, we explore the impact of the TGF-β signaling pathway using a transient zebrafish model for ALS. Our findings reveal that the knockdown of lead to a partial prevention of motor axon abnormalities and locomotor deficits in a transient ALS zebrafish model at 48 h post-fertilization (hpf). In this context, we delve into the proposed distinct roles of TGF-β in the progression of ALS. Indeed, some evidence suggests a dual role for TGF-β in ALS progression. Initially, it seems to exert a neuroprotective effect in the early stages, but paradoxically, it may contribute to disease progression in later stages. Consequently, we suggest that the TGF-β signaling pathway emerges as an attractive therapeutic target for treating ALS. Nevertheless, further research is crucial to comprehensively understand the nuanced role of TGF-β in the pathological context.

References
1.
Ismaeel A, Kim J, Kirk J, Smith R, Bohannon W, Koutakis P . Role of Transforming Growth Factor-β in Skeletal Muscle Fibrosis: A Review. Int J Mol Sci. 2019; 20(10). PMC: 6566291. DOI: 10.3390/ijms20102446. View

2.
Morrison B, Lachey J, Warsing L, Ting B, Pullen A, Underwood K . A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2009; 217(2):258-68. DOI: 10.1016/j.expneurol.2009.02.017. View

3.
Antony Day W, Koishi K, Nukuda H, McLennan I . Transforming growth factor-beta 2 causes an acute improvement in the motor performance of transgenic ALS mice. Neurobiol Dis. 2005; 19(1-2):323-30. DOI: 10.1016/j.nbd.2005.01.010. View

4.
Galbiati M, Crippa V, Rusmini P, Cristofani R, Messi E, Piccolella M . Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis. Int J Mol Sci. 2020; 21(12). PMC: 7352289. DOI: 10.3390/ijms21124291. View

5.
Gonzalez D, Contreras O, Rebolledo D, Espinoza J, van Zundert B, Brandan E . ALS skeletal muscle shows enhanced TGF-β signaling, fibrosis and induction of fibro/adipogenic progenitor markers. PLoS One. 2017; 12(5):e0177649. PMC: 5433732. DOI: 10.1371/journal.pone.0177649. View